Paper41999193
Efficacy and Safety Profile of a Rituximab, Methotrexate, and Thiotepa-Based Regimen in Newly Diagnosed Primary CNS Lymphoma.
Wang H and 10 others. Int J Cancer, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Efficacy and Safety Profile of a Rituximab, Methotrexate, and Thiotepa-Based Regimen in Newly Diagnosed Primary CNS Lymphoma. Papers, record 41999193. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41999193
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Efficacy and Safety Profile of a Rituximab, Methotrexate, and Thiotepa-Based Regimen in Newly Diagnosed Primary CNS Lymphoma.
- PubMed
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Central Nervous System Neoplasms | Major topic |
| Lymphoma, Large B-Cell, Diffuse | Major topic |
| Humans | |
| Rituximab | |
| Female | |
| Methotrexate | |
| Thiotepa | |
| Middle Aged | |
| Aged | |
| Retrospective Studies | |
| Male | |
| Adult | |
| Transplantation, Autologous | |
| Young Adult | |
| Progression-Free Survival | |
| Treatment Outcome |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| YDZJ202601ZYTS602 | Department of Finance of Jilin Province | PubMed |
Source PubMed
References29
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 39585484 | Advances in Primary Central Nervous System Lymphoma. | Curr Neurol Neurosci Rep | 2024 | https://conductscience.org/library/papers/39585484 | PubMed |
| 2 | 35004280 | Preliminary Evaluation of Zanubrutinib-Containing Regimens in DLBCL and the Cerebrospinal Fluid Distribution of Zanubrutinib: A 13-Case Series. | Front Oncol | 2021 | https://conductscience.org/library/papers/35004280 | PubMed |
| 3 | 35116520 | Bruton's tyrosine kinase inhibitors in primary central nervous system lymphoma-evaluation of anti-tumor efficacy and brain distribution. | Transl Cancer Res | 2021 | https://conductscience.org/library/papers/35116520 | PubMed |
| 4 | 32232989 | Outcomes of older patients with primary central nervous system lymphoma treated in routine clinical practice in the UK: methotrexate dose intensity correlates with response and survival. | Br J Haematol | 2020 | https://conductscience.org/library/papers/32232989 | PubMed |
| 5 | 31997308 | Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system - an international study of feasibility and efficacy in routine clinical practice. | Br J Haematol | 2020 | https://conductscience.org/library/papers/31997308 | PubMed |
| 6 | 37572086 | A phase 2 study of ibrutinib maintenance following first-line high-dose methotrexate-based chemotherapy for elderly patients with primary central nervous system lymphoma. | Cancer | 2023 | https://conductscience.org/library/papers/37572086 | PubMed |
| 7 | 36453110 | Methotrexate, cytarabine, thiotepa and rituximab (MATRix) chemoimmunotherapy for primary central nervous system lymphoma: a Toronto experience. | Haematologica | 2023 | https://conductscience.org/library/papers/36453110 | PubMed |
| 8 | 35096360 | Primary central nervous system lymphoma in the United States, 1975-2017. | Ther Adv Hematol | 2022 | https://conductscience.org/library/papers/35096360 | PubMed |
| 9 | 35562406 | Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. | Leukemia | 2022 | https://conductscience.org/library/papers/35562406 | PubMed |
| 10 | 39157596 | Sequential high-dose methotrexate and cytarabine administration improves outcomes in real-world patients with primary central nervous system lymphoma: A report from the Australasian Lymphoma Alliance. | EJHaem | 2024 | https://conductscience.org/library/papers/39157596 | PubMed |
| 11 | 38836097 | Primary central nervous system lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. | Hemasphere | 2024 | https://conductscience.org/library/papers/38836097 | PubMed |
| 12 | 39390309 | Novel Therapies for Primary Central Nervous System Lymphomas. | Curr Neurol Neurosci Rep | 2024 | https://conductscience.org/library/papers/39390309 | PubMed |
| 13 | 40275355 | PFS24 as a prognostic milestone in patients with newly diagnosed primary CNS lymphoma. | J Hematol Oncol | 2025 | https://conductscience.org/library/papers/40275355 | PubMed |
| 14 | 27132696 | Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. | Lancet Haematol | 2016 | https://conductscience.org/library/papers/27132696 | PubMed |
| 15 | 31907289 | Management and outcome of primary CNS lymphoma in the modern era: An LOC network study. | Neurology | 2020 | https://conductscience.org/library/papers/31907289 | PubMed |
| 16 | 40935174 | Real-world analysis of primary central nervous system diffuse large B-cell lymphoma. | Crit Rev Oncol Hematol | 2025 | https://conductscience.org/library/papers/40935174 | PubMed |
| 17 | 19767089 | High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. | Lancet | 2009 | https://conductscience.org/library/papers/19767089 | PubMed |
| 18 | 29054815 | Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. | Lancet Haematol | 2017 | https://conductscience.org/library/papers/29054815 | PubMed |
| 19 | 40652061 | Rituximab, high-dose methotrexate plus orelabrutinib as induction therapy in newly diagnosed primary central nervous system lymphoma. | Leukemia | 2025 | https://conductscience.org/library/papers/40652061 | PubMed |
| 20 | 36513674 | Rituximab with high-dose methotrexate is effective and cost-effective in newly diagnosed primary central nervous system lymphoma. | Sci Rep | 2022 | https://conductscience.org/library/papers/36513674 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41999193
GET https://conductscience.org/api/papers/v1/41999193/references?page=2